首页 > 最新文献

Asia Pacific Allergy最新文献

英文 中文
A paediatric case of exercise-augmented anaphylaxis following bee pollen ingestion in Western Australia. 西澳大利亚摄入蜂花粉后运动增强性过敏反应的儿科病例。
IF 1.7 Q3 ALLERGY Pub Date : 2022-07-12 eCollection Date: 2022-07-01 DOI: 10.5415/apallergy.2022.12.e23
Zhi Xiang Leang, Meera Thalayasingam, Michael O'Sullivan

Bee pollen is becoming an increasingly popular health supplement worldwide due to its many therapeutic applications. Thirteen cases of anaphylaxis to bee pollen consumption have been published to date, with plant pollen of the Compositae family being the most frequently implicated allergen. We present the first known paediatric case of bee pollen anaphylaxis in Australia involving a 15-year-old boy who had a strongly positive skin prick test to the bee pollen consumed where exercise was a possible co-factor. Our patient had a history of allergic rhinitis like most earlier cases. Our patient also had a strongly positive skin prick test to overseas-sourced bee pollen despite no relevant travel history, indicating the likelihood of a common pollen grain or cross-allergenicity of pollen grains found within both bee pollens. Our case reinforces the importance of a careful dietary history including health supplements when assessing for anaphylaxis.

蜂花粉正成为越来越受欢迎的保健品,由于它的许多治疗应用世界各地。迄今为止,已发表了13例蜂花粉过敏反应病例,其中菊科植物花粉是最常见的过敏原。我们提出了澳大利亚第一例已知的蜂花粉过敏反应的儿科病例,涉及一名15岁的男孩,他对消耗的蜂花粉进行了强烈阳性的皮肤点刺试验,其中运动可能是一个辅助因素。我们的病人和大多数早期病例一样有过敏性鼻炎的病史。尽管没有相关的旅行史,但患者对海外蜂花粉的皮肤点刺试验也呈强烈阳性,这表明两种蜂花粉中可能存在共同的花粉粒或交叉致敏性的花粉粒。我们的病例强调了在评估过敏反应时仔细的饮食史的重要性,包括健康补充剂。
{"title":"A paediatric case of exercise-augmented anaphylaxis following bee pollen ingestion in Western Australia.","authors":"Zhi Xiang Leang,&nbsp;Meera Thalayasingam,&nbsp;Michael O'Sullivan","doi":"10.5415/apallergy.2022.12.e23","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e23","url":null,"abstract":"<p><p>Bee pollen is becoming an increasingly popular health supplement worldwide due to its many therapeutic applications. Thirteen cases of anaphylaxis to bee pollen consumption have been published to date, with plant pollen of the Compositae family being the most frequently implicated allergen. We present the first known paediatric case of bee pollen anaphylaxis in Australia involving a 15-year-old boy who had a strongly positive skin prick test to the bee pollen consumed where exercise was a possible co-factor. Our patient had a history of allergic rhinitis like most earlier cases. Our patient also had a strongly positive skin prick test to overseas-sourced bee pollen despite no relevant travel history, indicating the likelihood of a common pollen grain or cross-allergenicity of pollen grains found within both bee pollens. Our case reinforces the importance of a careful dietary history including health supplements when assessing for anaphylaxis.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"12 3","pages":"e23"},"PeriodicalIF":1.7,"publicationDate":"2022-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/03/apa-12-e23.PMC9353203.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40697385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Patterns of allergenic food introduction in Los Angeles inner-city children. 洛杉矶市中心儿童过敏食物引入模式。
IF 1.7 Q3 ALLERGY Pub Date : 2022-07-12 eCollection Date: 2022-07-01 DOI: 10.5415/apallergy.2022.12.e24
Kenny Yat-Choi Kwong, Erica Chen, Paulina Tran, Sydney Leibel, Maryam Masood, Spencer Boyle, Lyne Scott

Background: Early introduction of allergenic foods is recommended to reduce the risk of developing food allergies, but it is unclear whether recommendations are being followed.

Objective: We examine patterns of allergenic food introduction in inner-city children enrolled in an academic pediatric practice in the greater Los Angeles area.

Methods: This was a prospective study with patients ages 12 to 24 months recruited from the pediatrics continuity clinic at an inner-city tertiary medical center in the greater Los Angeles area. Caregivers were asked via anonymous surveys about their child's history of atopic diseases and at what age they first introduced egg, soy, wheat, peanut, tree nuts, fish, shrimp, and shellfish into their child's diet.

Results: Two hundred caregivers responded to the survey. The average age of introduction of egg was 9.2 months, soy 10 months, wheat 9.3 months, peanut 10.5 months, tree nuts 10.9 months, fish 10.9 months, shrimp 11.3 months, and shellfish 11.5 months. Between ages 4-11 months, 65.3% of children were introduced egg, 19.1% soy, 55.8% wheat, 28.6% peanut, 17.1% tree nuts, 28.1% fish, 13.6% shrimp, and 7.0% shellfish. By age 24 months, 92% of children were introduced egg, 37.7% soy, 85.4% wheat, 67.3% peanut, 47.7% tree nuts, 67.8% fish, 48.2% shrimp, and 30.2% shellfish. Of the 14 children with eczema or egg allergy, 26.1% were introduced peanut by age 4-6 months and 50% by age 4-11 months.

Conclusion: Despite recommendations, inner-city caregivers may not be introducing allergenic foods in a timely manner to their children.

背景:建议尽早摄入致敏食物以降低发生食物过敏的风险,但目前尚不清楚这些建议是否得到遵守。目的:我们检查在大洛杉矶地区参加学术儿科实践的内城儿童的过敏性食物引入模式。方法:这是一项前瞻性研究,从大洛杉矶地区内城三级医疗中心的儿科连续性诊所招募年龄在12至24个月的患者。通过匿名调查,护理人员被问及他们孩子的特应性疾病史,以及他们第一次在孩子的饮食中引入鸡蛋、大豆、小麦、花生、树坚果、鱼、虾和贝类的年龄。结果:200名护理人员参与了调查。鸡蛋的平均引进年龄为9.2个月,大豆10个月,小麦9.3个月,花生10.5个月,坚果10.9个月,鱼类10.9个月,虾11.3个月,贝类11.5个月。在4-11个月之间,65.3%的儿童食用鸡蛋,19.1%食用大豆,55.8%食用小麦,28.6%食用花生,17.1%食用树坚果,28.1%食用鱼类,13.6%食用虾,7.0%食用贝类。到24个月大时,92%的儿童食用鸡蛋,37.7%的大豆,85.4%的小麦,67.3%的花生,47.7%的树坚果,67.8%的鱼,48.2%的虾和30.2%的贝类。在14名湿疹或鸡蛋过敏的儿童中,26.1%的儿童在4-6个月大时开始接触花生,50%的儿童在4-11个月大时开始接触花生。结论:尽管有这些建议,但市中心的看护人可能没有及时向他们的孩子介绍致敏食物。
{"title":"Patterns of allergenic food introduction in Los Angeles inner-city children.","authors":"Kenny Yat-Choi Kwong,&nbsp;Erica Chen,&nbsp;Paulina Tran,&nbsp;Sydney Leibel,&nbsp;Maryam Masood,&nbsp;Spencer Boyle,&nbsp;Lyne Scott","doi":"10.5415/apallergy.2022.12.e24","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e24","url":null,"abstract":"<p><strong>Background: </strong>Early introduction of allergenic foods is recommended to reduce the risk of developing food allergies, but it is unclear whether recommendations are being followed.</p><p><strong>Objective: </strong>We examine patterns of allergenic food introduction in inner-city children enrolled in an academic pediatric practice in the greater Los Angeles area.</p><p><strong>Methods: </strong>This was a prospective study with patients ages 12 to 24 months recruited from the pediatrics continuity clinic at an inner-city tertiary medical center in the greater Los Angeles area. Caregivers were asked via anonymous surveys about their child's history of atopic diseases and at what age they first introduced egg, soy, wheat, peanut, tree nuts, fish, shrimp, and shellfish into their child's diet.</p><p><strong>Results: </strong>Two hundred caregivers responded to the survey. The average age of introduction of egg was 9.2 months, soy 10 months, wheat 9.3 months, peanut 10.5 months, tree nuts 10.9 months, fish 10.9 months, shrimp 11.3 months, and shellfish 11.5 months. Between ages 4-11 months, 65.3% of children were introduced egg, 19.1% soy, 55.8% wheat, 28.6% peanut, 17.1% tree nuts, 28.1% fish, 13.6% shrimp, and 7.0% shellfish. By age 24 months, 92% of children were introduced egg, 37.7% soy, 85.4% wheat, 67.3% peanut, 47.7% tree nuts, 67.8% fish, 48.2% shrimp, and 30.2% shellfish. Of the 14 children with eczema or egg allergy, 26.1% were introduced peanut by age 4-6 months and 50% by age 4-11 months.</p><p><strong>Conclusion: </strong>Despite recommendations, inner-city caregivers may not be introducing allergenic foods in a timely manner to their children.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"12 3","pages":"e24"},"PeriodicalIF":1.7,"publicationDate":"2022-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ab/a6/apa-12-e24.PMC9353202.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40413401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Erythrodermic psoriasis in post-coronavirus disease 2019 patient 2019冠状病毒病后患者的红皮病性银屑病
IF 1.7 Q3 ALLERGY Pub Date : 2022-04-01 DOI: 10.5415/apallergy.2022.12.e16
Irwanida Batubara, W. Budianti
Erythrodermic psoriasis (EP) is characterized by generalized erythema and desquamation affecting more than 75% of body surface area and usually accompanied by systemic symptoms. The triggers are medication withdrawal, drugs reactions, and systemic infections including coronavirus disease 2019 (COVID-19). A 46-year-old man with plaque psoriasis suffered from EP following the sudden discontinuation of medications. He was diagnosed with COVID-19 one month before erythroderma appeared. The body surface area involvement was 96% and psoriasis area severity index was 49.8. His general condition and laboratory examination were within normal limits. He was treated with cyclosporine-A for one month after being healed from COVID-19 with significant improvement. Excessive production of proinflammatory cytokines in COVID-19 plays a role in the pathogenesis of psoriasis. This condition should be managed appropriately to minimize the complication. Cyclosporine-A is the first-line therapy for EP because of its effectiveness and good safety profile. It is also shown a beneficial effect in COVID-19 infection in vitro.
红皮病型牛皮癣(EP)的特点是全身红斑和脱屑,影响体表面积的75%以上,通常伴有全身症状。触发因素包括停药、药物反应和包括2019冠状病毒病(COVID-19)在内的全身性感染。一位46岁的斑块型银屑病患者在突然停药后发生EP。他在出现红皮病前一个月被诊断为COVID-19。体表受累率96%,银屑病严重程度指数49.8。他的一般情况和实验室检查在正常范围内。新冠肺炎痊愈后给予环孢素- a治疗1个月,病情明显好转。COVID-19中促炎细胞因子的过量产生在牛皮癣的发病机制中起作用。这种情况应适当处理,以尽量减少并发症。环孢素- a因其有效性和良好的安全性而成为EP的一线治疗药物。在体外对COVID-19感染也显示出有益的效果。
{"title":"Erythrodermic psoriasis in post-coronavirus disease 2019 patient","authors":"Irwanida Batubara, W. Budianti","doi":"10.5415/apallergy.2022.12.e16","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e16","url":null,"abstract":"Erythrodermic psoriasis (EP) is characterized by generalized erythema and desquamation affecting more than 75% of body surface area and usually accompanied by systemic symptoms. The triggers are medication withdrawal, drugs reactions, and systemic infections including coronavirus disease 2019 (COVID-19). A 46-year-old man with plaque psoriasis suffered from EP following the sudden discontinuation of medications. He was diagnosed with COVID-19 one month before erythroderma appeared. The body surface area involvement was 96% and psoriasis area severity index was 49.8. His general condition and laboratory examination were within normal limits. He was treated with cyclosporine-A for one month after being healed from COVID-19 with significant improvement. Excessive production of proinflammatory cytokines in COVID-19 plays a role in the pathogenesis of psoriasis. This condition should be managed appropriately to minimize the complication. Cyclosporine-A is the first-line therapy for EP because of its effectiveness and good safety profile. It is also shown a beneficial effect in COVID-19 infection in vitro.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45756426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Treatment-resistant atopic dermatitis: novel therapeutics, digital tools, and precision medicine 耐治疗性特应性皮炎:新疗法、数字工具和精准医学
IF 1.7 Q3 ALLERGY Pub Date : 2022-04-01 DOI: 10.5415/apallergy.2022.12.e20
P. Naik
Atopic dermatitis (AD) is a prevalent condition impacting up to 25% of children and 8% of adults worldwide. An estimated 20% of those with AD comprise a subset of patients with treatment-resistant AD, for whom traditional therapeutics and management strategies are unsuccessful. Physical symptoms significantly impact quality of life for patients and caregivers. The condition is chronic and may persist throughout the lifespan with recurrent episodes. Novel AD therapeutics offer new opportunities to resolve symptoms of treatment-resistant more effectively AD. Recently developed pharmacological agents were developed with an appreciation of AD as a heterogeneous condition. New advances include topical, oral, and injectable therapeutics with novel mechanisms of action. In addition, advances in clinical practice, including the application of digital tools, can promote a personalized medicine approach. For example, teledermatology for chronic conditions such as AD have been embraced by clinicians and patients; communicating symptoms via photographs can augment patient symptom trackers and aid trigger identification. Digital tools can also be used to increase medication adherence and improve patient/caregiver engagement. Integrating the above is a personalized medicine approach. Advanced therapeutics with novel mechanisms of action, integrated with digital tools, and trends toward patient-centered medicine can assist this chronic, heterogeneous condition via precision medicine and better treat treatment-resistant AD.
特应性皮炎(AD)是一种普遍的疾病,影响着全球高达25%的儿童和8%的成年人。据估计,20%的AD患者是耐治疗AD患者的一部分,传统的治疗和管理策略对他们来说是不成功的。身体症状显著影响患者和护理人员的生活质量。这种情况是慢性的,可能会在一生中反复发作。新的AD治疗方法为更有效地解决治疗耐药性AD的症状提供了新的机会。最近开发的药物被认为是一种异质性疾病。新的进展包括具有新作用机制的局部、口服和注射疗法。此外,临床实践的进步,包括数字工具的应用,可以促进个性化的医疗方法。例如,针对AD等慢性疾病的远程皮肤科已经被临床医生和患者所接受;通过照片交流症状可以增强患者症状跟踪器并帮助识别触发因素。数字工具也可用于提高药物依从性和提高患者/护理人员的参与度。整合以上内容是一种个性化的医学方法。具有新作用机制的先进疗法,与数字工具相结合,以及以患者为中心的医学趋势,可以通过精准医学来帮助这种慢性、异质性疾病,并更好地治疗耐药AD。
{"title":"Treatment-resistant atopic dermatitis: novel therapeutics, digital tools, and precision medicine","authors":"P. Naik","doi":"10.5415/apallergy.2022.12.e20","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e20","url":null,"abstract":"Atopic dermatitis (AD) is a prevalent condition impacting up to 25% of children and 8% of adults worldwide. An estimated 20% of those with AD comprise a subset of patients with treatment-resistant AD, for whom traditional therapeutics and management strategies are unsuccessful. Physical symptoms significantly impact quality of life for patients and caregivers. The condition is chronic and may persist throughout the lifespan with recurrent episodes. Novel AD therapeutics offer new opportunities to resolve symptoms of treatment-resistant more effectively AD. Recently developed pharmacological agents were developed with an appreciation of AD as a heterogeneous condition. New advances include topical, oral, and injectable therapeutics with novel mechanisms of action. In addition, advances in clinical practice, including the application of digital tools, can promote a personalized medicine approach. For example, teledermatology for chronic conditions such as AD have been embraced by clinicians and patients; communicating symptoms via photographs can augment patient symptom trackers and aid trigger identification. Digital tools can also be used to increase medication adherence and improve patient/caregiver engagement. Integrating the above is a personalized medicine approach. Advanced therapeutics with novel mechanisms of action, integrated with digital tools, and trends toward patient-centered medicine can assist this chronic, heterogeneous condition via precision medicine and better treat treatment-resistant AD.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46125987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Senile erythroderma with hyper IgE: an independent and novel disease form 老年红皮病伴高IgE:一种独立的新型疾病
IF 1.7 Q3 ALLERGY Pub Date : 2022-04-01 DOI: 10.5415/apallergy.2022.12.e12
Y. Horiuchi
Erythroderma is a rare exfoliative dermatitis with various causes [1, 2]. The exact pathophysiology of this disease has not received much attention. Moreover, while it has been reviewed many times [1, 2], there is little mention of senile erythroderma. The accumulated findings [1, 2] reveal 3 factors involved in its etiology: drugs such as carbamazepine, preexisting skin diseases such as psoriasis [1], and stages of malignancies such as cutaneous T-cell lymphomas. Li and Zheng [2] reported the most prevalent causative factors—preexisting dermatoses (70.77%), followed by idiopathic causes (14.23%), drug-induced reactions (12.69%), and malignancies (2.31%). Among the pre-existing dermatoses, psoriasis was the most common etiology (55%). Several case analyses show that males are 4 times more likely to be affected by erythroderma than females [1, 2]. The average age is 52 to 57 years, including those in 80s [1, 2]. One study reported a unique case of erythroderma caused by propolis [3]—a food product produced by honeybees. Steroid withdrawal erythroderma [4] has been reported; as it is caused by medical care, it is called iatrogenic. Patients with systemic eczema have received steroids for external use at various medical institutions for many years due to the intractability of their conditions. In cases of steroid withdrawal, erythroderma occasionally occurs. As the cases caused by an underlying disease are diverse, dermatologists and clinicians should first determine the possible cause in patients with erythroderma.
红皮病是一种罕见的剥脱性皮炎,病因多种多样[1,2]。这种疾病的确切病理生理学尚未得到太多关注。此外,尽管它已经被多次审查[1,2],但很少提及老年性红皮病。累积的研究结果[1,2]揭示了与其病因有关的3个因素:药物如卡马西平、先前存在的皮肤病如银屑病[1]和恶性肿瘤分期如皮肤T细胞淋巴瘤。李和郑[2]报道了最常见的致病因素——预先存在的皮肤病(70.77%),其次是特发性病因(14.23%)、药物反应(12.69%)和恶性肿瘤(2.31%)。在预先存在的皮病中,银屑病是最常见的病因(55%)。一些病例分析表明,男性受红皮病影响的可能性是女性的4倍[1,2]。平均年龄为52至57岁,其中80多岁[1,2]。一项研究报告了一例由蜜蜂生产的食物蜂胶引起的红皮病。类固醇戒断性红皮病[4]已有报道;由于它是由医疗保健引起的,所以被称为医源性。系统性湿疹患者由于病情难以控制,多年来一直在各种医疗机构接受类固醇外用治疗。在停用类固醇的情况下,偶尔会发生红皮病。由于潜在疾病引起的病例多种多样,皮肤科医生和临床医生应首先确定红皮病患者的可能原因。
{"title":"Senile erythroderma with hyper IgE: an independent and novel disease form","authors":"Y. Horiuchi","doi":"10.5415/apallergy.2022.12.e12","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e12","url":null,"abstract":"Erythroderma is a rare exfoliative dermatitis with various causes [1, 2]. The exact pathophysiology of this disease has not received much attention. Moreover, while it has been reviewed many times [1, 2], there is little mention of senile erythroderma. The accumulated findings [1, 2] reveal 3 factors involved in its etiology: drugs such as carbamazepine, preexisting skin diseases such as psoriasis [1], and stages of malignancies such as cutaneous T-cell lymphomas. Li and Zheng [2] reported the most prevalent causative factors—preexisting dermatoses (70.77%), followed by idiopathic causes (14.23%), drug-induced reactions (12.69%), and malignancies (2.31%). Among the pre-existing dermatoses, psoriasis was the most common etiology (55%). Several case analyses show that males are 4 times more likely to be affected by erythroderma than females [1, 2]. The average age is 52 to 57 years, including those in 80s [1, 2]. One study reported a unique case of erythroderma caused by propolis [3]—a food product produced by honeybees. Steroid withdrawal erythroderma [4] has been reported; as it is caused by medical care, it is called iatrogenic. Patients with systemic eczema have received steroids for external use at various medical institutions for many years due to the intractability of their conditions. In cases of steroid withdrawal, erythroderma occasionally occurs. As the cases caused by an underlying disease are diverse, dermatologists and clinicians should first determine the possible cause in patients with erythroderma.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47809836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between self-reported drug hypersensitivity reactions and psychological disorders. 自我报告的药物超敏反应与心理障碍的关系。
IF 1.7 Q3 ALLERGY Pub Date : 2022-04-01 DOI: 10.5415/apallergy.2022.12.e15
Inês Machado Cunha, Joana Gouveia, Eva Gomes

Background: Medically unexplained physical symptoms are a well-recognized problem and, in some cases, there is a well-established relationship between behavior and psychopathological disturbances. However, the association between drug hypersensitivity reactions and psychoactive disorders stills under discussion.

Objective: Our main goal was to establish if there is an association between self-reported drug hypersensitivity reaction and psychopathology with need for psychoactive drug consumption.

Methods: Retrospective study of adult patients evaluated in a first Immunoallergology appointment because of self-reported drug hypersensitivity over 1 year and register of data concerning psychoactive drugs use. Compare the study group with patients observed for allergic respiratory disease along the same year.

Results: The study group included 70 patients that referred a total of 92 self-reported drug hypersensitivity reactions. Twenty-nine (41.4%) were under treatment with psychoactive drugs: 20 (70%) were treated with anxiolytics, 13 (18.6%) with antidepressants, 15 (21.4%) with sedatives, and 1 (1.4%) with antipsychotics. The control group included 160 patients and 38 patients (23.8%) were under treatment with psychoactive drugs: 31 (19.4%) where treated with antidepressants, 29 (18.1%) with anxiolytics, and 3 (1.9%) with sedatives. The use of psychoactive drugs in the study group is higher than in the control group (p = 0.007), the difference is especially important for sedative drugs (p < 0.001). Besides a higher use of psychoactive drugs, the study group also has a higher frequency of use of several psychoactive drug (p = 0.002).

Conclusion: Patients with a self-report drug hypersensitivity have more tendency to be under treatment with psychoactive drugs and could have more tendency to somatization. Personality traces and psychopathology must be taken into account during an allergy workup.

背景:医学上无法解释的身体症状是一个公认的问题,在某些情况下,行为与精神病理障碍之间存在着明确的关系。然而,药物超敏反应与精神障碍之间的关系仍在讨论中。目的:我们的主要目的是确定自我报告的药物超敏反应和精神病理与精神活性药物消费需求之间是否存在关联。方法:回顾性研究因自我报告药物过敏1年以上而在免疫过敏科首次就诊的成年患者,并登记有关精神活性药物使用的资料。将研究组与同一年观察到的过敏性呼吸道疾病患者进行比较。结果:研究组包括70例患者,共涉及92例自我报告的药物过敏反应。其中,抗焦虑药20例(70%),抗抑郁药13例(18.6%),镇静剂15例(21.4%),抗精神病药1例(1.4%)。对照组160例,精神药物治疗38例(23.8%),其中抗抑郁药31例(19.4%),抗焦虑药29例(18.1%),镇静剂3例(1.9%)。研究组精神活性药物的使用高于对照组(p = 0.007),其中镇静药物的使用差异尤为显著(p < 0.001)。研究组除使用精神活性药物较高外,几种精神活性药物的使用频率也较高(p = 0.002)。结论:自我报告药物超敏的患者更容易接受精神活性药物的治疗,更容易出现躯体化。在过敏检查中,必须考虑到性格和精神病理。
{"title":"Association between self-reported drug hypersensitivity reactions and psychological disorders.","authors":"Inês Machado Cunha,&nbsp;Joana Gouveia,&nbsp;Eva Gomes","doi":"10.5415/apallergy.2022.12.e15","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e15","url":null,"abstract":"<p><strong>Background: </strong>Medically unexplained physical symptoms are a well-recognized problem and, in some cases, there is a well-established relationship between behavior and psychopathological disturbances. However, the association between drug hypersensitivity reactions and psychoactive disorders stills under discussion.</p><p><strong>Objective: </strong>Our main goal was to establish if there is an association between self-reported drug hypersensitivity reaction and psychopathology with need for psychoactive drug consumption.</p><p><strong>Methods: </strong>Retrospective study of adult patients evaluated in a first Immunoallergology appointment because of self-reported drug hypersensitivity over 1 year and register of data concerning psychoactive drugs use. Compare the study group with patients observed for allergic respiratory disease along the same year.</p><p><strong>Results: </strong>The study group included 70 patients that referred a total of 92 self-reported drug hypersensitivity reactions. Twenty-nine (41.4%) were under treatment with psychoactive drugs: 20 (70%) were treated with anxiolytics, 13 (18.6%) with antidepressants, 15 (21.4%) with sedatives, and 1 (1.4%) with antipsychotics. The control group included 160 patients and 38 patients (23.8%) were under treatment with psychoactive drugs: 31 (19.4%) where treated with antidepressants, 29 (18.1%) with anxiolytics, and 3 (1.9%) with sedatives. The use of psychoactive drugs in the study group is higher than in the control group (<i>p</i> = 0.007), the difference is especially important for sedative drugs (<i>p</i> < 0.001). Besides a higher use of psychoactive drugs, the study group also has a higher frequency of use of several psychoactive drug (<i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>Patients with a self-report drug hypersensitivity have more tendency to be under treatment with psychoactive drugs and could have more tendency to somatization. Personality traces and psychopathology must be taken into account during an allergy workup.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"12 2","pages":"e15"},"PeriodicalIF":1.7,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/1b/apa-12-e15.PMC9066087.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10242728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
PSAAI@50: Celebrating gold… and beyond! PSAAI@50:庆祝金牌……以及更多!
IF 1.7 Q3 ALLERGY Pub Date : 2022-04-01 DOI: 10.5415/apallergy.2022.12.e18
Maria Carmela Kasala
{"title":"PSAAI@50: Celebrating gold… and beyond!","authors":"Maria Carmela Kasala","doi":"10.5415/apallergy.2022.12.e18","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e18","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45901443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronavirus disease 2019 (COVID-19) and Long COVID 2019冠状病毒病(新冠肺炎)和长期新冠肺炎
IF 1.7 Q3 ALLERGY Pub Date : 2022-04-01 DOI: 10.5415/apallergy.2022.12.e22
Yoon-Seok Chang
https://apallergy.org The coronavirus disease 2019 (COVID-19) pandemic has impacted every aspect of our lives. We lost our patients, colleagues, friends, and family members. Most countries experienced lockdowns. Wearing a face mask, physical distance, washing hands, and vaccination are the essential components of the preventive measure. We got used to have online or virtual meetings. It is still an ongoing global pandemic. However, after the Omicron, a variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), became dominant, some countries are starting to lift the regulations with the policy of “living with COVID.” For example, at the moment, it is no longer mandatory to wear a face mask in United Kingdom (UK) where the WAO-BASCI 2022 UK Conference was held (Edinburgh, Scotland, April 25–27, 2022). It was a very successful face to face international congress with a lot of learning and networking.
https://apallergy.org2019冠状病毒病(新冠肺炎)大流行影响了我们生活的方方面面。我们失去了病人、同事、朋友和家人。大多数国家都经历了封锁。戴口罩、保持身体距离、洗手和接种疫苗是预防措施的重要组成部分。我们习惯了在线或虚拟会议。这仍然是一场持续的全球流行病。然而,在严重急性呼吸系统综合征冠状病毒2型的变种奥密克戎占主导地位后,一些国家开始以“与新冠病毒共存”的政策取消规定。例如,目前,在WAO-BASCI 2022英国会议举行地英国(2022年4月25日至27日,苏格兰爱丁堡),不再强制佩戴口罩。这是一次非常成功的面对面国际大会,有很多学习和交流。
{"title":"Coronavirus disease 2019 (COVID-19) and Long COVID","authors":"Yoon-Seok Chang","doi":"10.5415/apallergy.2022.12.e22","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e22","url":null,"abstract":"https://apallergy.org The coronavirus disease 2019 (COVID-19) pandemic has impacted every aspect of our lives. We lost our patients, colleagues, friends, and family members. Most countries experienced lockdowns. Wearing a face mask, physical distance, washing hands, and vaccination are the essential components of the preventive measure. We got used to have online or virtual meetings. It is still an ongoing global pandemic. However, after the Omicron, a variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), became dominant, some countries are starting to lift the regulations with the policy of “living with COVID.” For example, at the moment, it is no longer mandatory to wear a face mask in United Kingdom (UK) where the WAO-BASCI 2022 UK Conference was held (Edinburgh, Scotland, April 25–27, 2022). It was a very successful face to face international congress with a lot of learning and networking.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46610817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Characteristics of the European Thoracic Society/American Thoracic Society severe asthma definition as a determinant of future use of biologics/bronchial thermoplasty 欧洲胸科协会/美国胸科协会将重度哮喘定义为未来使用生物制剂/支气管热成形术的决定因素
IF 1.7 Q3 ALLERGY Pub Date : 2022-04-01 DOI: 10.5415/apallergy.2022.12.e13
H. Nishiyama, Y. Kanemitsu, Kensuke Fukumitsu, N. Takeda, Ryota Kurokawa, T. Tajiri, K. Ito, Jenifer Maries Go Yap, S. Fukuda, T. Uemura, H. Ohkubo, K. Maeno, Y. Ito, T. Oguri, M. Takemura, A. Niimi
Background International guidelines define severe uncontrolled asthma. Biologics or bronchial thermoplasty (Bio/BT) are recommended for such patients. Objectives To determine which definitions of severe uncontrolled asthma are associated with an additional Bio/BT treatment in patients with severe uncontrolled asthma. Methods Consecutive 107 asthmatics (including 15 patients for whom Bio/BT was introduced within 3 months after examination), classified as treatment step 4 according to the Global Initiative for Asthma 2015 guideline, were eligible for this analysis. Patients were assessed using the European Thoracic Society/American Thoracic Society (ERS/ATS) severe uncontrolled asthma guideline as defined by these 4 characteristics: poor control (ACT < 20), frequent exacerbations (≥2/yr), admissions (≥1/yr), and airflow limitation (forced expiratory volume in 1 second < 80% of predicted), along with comorbidities, and biomarkers, including blood granulocytes, fractional nitric oxide, and capsaicin cough reflex sensitivity (C-CS). These indices were compared between patients with and without Bio/BT introduction, and multivariate logistic regression analysis was performed to determine the association of the 4 definitions with treatment needs for Bio/BT. Results Patients who were introduced to Bio/BT had heightened C-CS, heavier smoking history, and a greater prevalence of diabetes mellitus than those without (p < 0.05). Poor asthma control (ACT < 20), frequent exacerbations (≥2/yr), and admissions (≥1/yr) were relevant to the future use of Bio/BT in the multivariate regression analysis. Type 2-related biomarkers including absolute eosinophil counts were higher in patients in the Bio introduction group than in the BT introduction group. Meanwhile, there was no significant difference of the 4 characteristics of severe uncontrolled asthma definition between patients in the Bio and those in the BT groups. Conclusion Although multiple factors such as treatment cost and asthma phenotypes affect treatment decision-making, the definition of poor asthma control, frequent exacerbations and admission by the ERS/ATS guidelines were important factors for an additional intensive treatment for severe uncontrolled asthma. Trial Registration UMIN Clinical Trials Registry: UMIN000024734
国际指南定义了严重不受控制的哮喘。对于此类患者,建议使用生物制剂或支气管热成形术(Bio/BT)。目的:确定哪些严重不受控制哮喘定义与严重不受控制哮喘患者额外的生物/BT治疗相关。方法连续107例哮喘患者(包括15例在检查后3个月内引入生物/BT的患者),根据全球哮喘倡议2015指南分类为治疗步骤4,符合本分析的条件。采用欧洲胸科学会/美国胸科学会(ERS/ATS)严重不受控制哮喘指南对患者进行评估,该指南由以下4个特征定义:控制不良(ACT < 20)、频繁发作(≥2次/年)、入院(≥1次/年)和气流受限(1秒用力呼气量<预测的80%),以及合共病和生物标志物,包括血液粒细胞、分数一氧化氮和辣椒素咳嗽反射敏感性(C-CS)。将这些指标在引入和未引入生物/BT的患者之间进行比较,并进行多因素logistic回归分析,以确定4种定义与生物/BT治疗需求的相关性。结果引入Bio/BT的患者C-CS升高,吸烟史加重,糖尿病患病率高于未引入Bio/BT的患者(p < 0.05)。在多因素回归分析中,哮喘控制不良(ACT < 20)、频繁发作(≥2次/年)和入院(≥1次/年)与未来使用Bio/BT相关。2型相关生物标志物,包括绝对嗜酸性粒细胞计数,生物引入组患者高于BT引入组患者。同时,生物组患者与BT组患者严重未控制哮喘定义的4个特征无显著差异。结论虽然治疗费用和哮喘表型等多种因素影响治疗决策,但哮喘控制不良的定义、频繁加重和根据ERS/ATS指南入院是对严重未控制哮喘进行额外强化治疗的重要因素。临床试验注册:UMIN000024734
{"title":"Characteristics of the European Thoracic Society/American Thoracic Society severe asthma definition as a determinant of future use of biologics/bronchial thermoplasty","authors":"H. Nishiyama, Y. Kanemitsu, Kensuke Fukumitsu, N. Takeda, Ryota Kurokawa, T. Tajiri, K. Ito, Jenifer Maries Go Yap, S. Fukuda, T. Uemura, H. Ohkubo, K. Maeno, Y. Ito, T. Oguri, M. Takemura, A. Niimi","doi":"10.5415/apallergy.2022.12.e13","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e13","url":null,"abstract":"Background International guidelines define severe uncontrolled asthma. Biologics or bronchial thermoplasty (Bio/BT) are recommended for such patients. Objectives To determine which definitions of severe uncontrolled asthma are associated with an additional Bio/BT treatment in patients with severe uncontrolled asthma. Methods Consecutive 107 asthmatics (including 15 patients for whom Bio/BT was introduced within 3 months after examination), classified as treatment step 4 according to the Global Initiative for Asthma 2015 guideline, were eligible for this analysis. Patients were assessed using the European Thoracic Society/American Thoracic Society (ERS/ATS) severe uncontrolled asthma guideline as defined by these 4 characteristics: poor control (ACT < 20), frequent exacerbations (≥2/yr), admissions (≥1/yr), and airflow limitation (forced expiratory volume in 1 second < 80% of predicted), along with comorbidities, and biomarkers, including blood granulocytes, fractional nitric oxide, and capsaicin cough reflex sensitivity (C-CS). These indices were compared between patients with and without Bio/BT introduction, and multivariate logistic regression analysis was performed to determine the association of the 4 definitions with treatment needs for Bio/BT. Results Patients who were introduced to Bio/BT had heightened C-CS, heavier smoking history, and a greater prevalence of diabetes mellitus than those without (p < 0.05). Poor asthma control (ACT < 20), frequent exacerbations (≥2/yr), and admissions (≥1/yr) were relevant to the future use of Bio/BT in the multivariate regression analysis. Type 2-related biomarkers including absolute eosinophil counts were higher in patients in the Bio introduction group than in the BT introduction group. Meanwhile, there was no significant difference of the 4 characteristics of severe uncontrolled asthma definition between patients in the Bio and those in the BT groups. Conclusion Although multiple factors such as treatment cost and asthma phenotypes affect treatment decision-making, the definition of poor asthma control, frequent exacerbations and admission by the ERS/ATS guidelines were important factors for an additional intensive treatment for severe uncontrolled asthma. Trial Registration UMIN Clinical Trials Registry: UMIN000024734","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47719119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Clinical characteristics of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A single-center study. 药物性Stevens-Johnson综合征和中毒性表皮坏死松解的临床特征:一项单中心研究。
IF 1.7 Q3 ALLERGY Pub Date : 2022-04-01 DOI: 10.5415/apallergy.2022.12.e17
Hye Won Yoo, Hye-Young Kim, Kihyuk Shin, Seong Heon Kim

Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe adverse cutaneous reactions, most commonly triggered by medications, characterized by extensive necrosis and detachment of the epidermis.

Objective: We investigated the differences in clinical characteristics of drug-induced SJS/TEN depending on the type of drug in a single center.

Methods: The relevance of sex, age, culprit drugs, clinical features, courses, treatment options, and follow-up results were retrospectively evaluated in patients diagnosed with drug-induced SJS/TEN at Pusan National University Hospital between 2008 and 2019.

Results: Ninety-two patients with a mean age of 58.7 ± 20.2 years (range, 10-93 years) were included in the study. Those aged 60-80 years accounted for the largest number of patients (42.4%). Patients with drug-induced SJS/TEN comprised 40 women (43.5%) and 52 men (56.5%). We categorized drug-induced SJS/TEN cases by culprit drugs into 6 groups: antibiotics, allopurinol, antiepileptic (AED), nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and other drugs. The rate of NSAID-induced disease significantly increased from SJS to TEN (p = 0.016). Among the patients in the NSAID group, the proportion of TEN (40%) was higher than that in the other groups (p = 0.021). The mean body surface area was significantly lower in the AED group than in the non-AED groups (7.1 ± 9.8 vs. 23.1 ± 27.3, p = 0.020) and higher in the NSAID group than in the non-NSAID groups (47.5 ± 39.5 vs. 15.7 ± 20.0, p = 0.010).

Conclusion: This study showed that the clinical characteristics of each causative drug group may be different in drug-induced SJS/TEN. Our findings may help clinicians better understand drug-induced SJS/TEN.

背景:Stevens-Johnson综合征(SJS)和中毒性表皮坏死松解症(TEN)是严重的皮肤不良反应,最常由药物引发,以表皮广泛坏死和脱离为特征。目的:探讨单中心药物性SJS/TEN在不同药物类型下的临床特征差异。方法:回顾性评价2008 - 2019年釜山国立大学医院诊断为药物性SJS/TEN患者的性别、年龄、罪魁祸首药物、临床特征、病程、治疗方案和随访结果的相关性。结果:92例患者纳入研究,平均年龄58.7±20.2岁(范围10-93岁)。60 ~ 80岁患者占比最大(42.4%)。药物性SJS/TEN患者中女性40例(43.5%),男性52例(56.5%)。我们将药物性SJS/TEN病例按罪魁祸首药物分为抗生素、别嘌呤醇、抗癫痫药(AED)、非甾体抗炎药(NSAIDs)、对乙酰氨基酚和其他药物6组。从SJS到TEN,非甾体抗炎药引起的疾病发生率显著增加(p = 0.016)。在NSAID组患者中,TEN的比例(40%)高于其他组(p = 0.021)。AED组的平均体表面积显著低于非AED组(7.1±9.8比23.1±27.3,p = 0.020), NSAID组的平均体表面积显著高于非NSAID组(47.5±39.5比15.7±20.0,p = 0.010)。结论:本研究显示药物性SJS/TEN各致药组的临床特征可能不同。我们的发现可能有助于临床医生更好地理解药物诱导的SJS/TEN。
{"title":"Clinical characteristics of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A single-center study.","authors":"Hye Won Yoo,&nbsp;Hye-Young Kim,&nbsp;Kihyuk Shin,&nbsp;Seong Heon Kim","doi":"10.5415/apallergy.2022.12.e17","DOIUrl":"https://doi.org/10.5415/apallergy.2022.12.e17","url":null,"abstract":"<p><strong>Background: </strong>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe adverse cutaneous reactions, most commonly triggered by medications, characterized by extensive necrosis and detachment of the epidermis.</p><p><strong>Objective: </strong>We investigated the differences in clinical characteristics of drug-induced SJS/TEN depending on the type of drug in a single center.</p><p><strong>Methods: </strong>The relevance of sex, age, culprit drugs, clinical features, courses, treatment options, and follow-up results were retrospectively evaluated in patients diagnosed with drug-induced SJS/TEN at Pusan National University Hospital between 2008 and 2019.</p><p><strong>Results: </strong>Ninety-two patients with a mean age of 58.7 ± 20.2 years (range, 10-93 years) were included in the study. Those aged 60-80 years accounted for the largest number of patients (42.4%). Patients with drug-induced SJS/TEN comprised 40 women (43.5%) and 52 men (56.5%). We categorized drug-induced SJS/TEN cases by culprit drugs into 6 groups: antibiotics, allopurinol, antiepileptic (AED), nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and other drugs. The rate of NSAID-induced disease significantly increased from SJS to TEN (<i>p</i> = 0.016). Among the patients in the NSAID group, the proportion of TEN (40%) was higher than that in the other groups (<i>p</i> = 0.021). The mean body surface area was significantly lower in the AED group than in the non-AED groups (7.1 ± 9.8 vs. 23.1 ± 27.3, <i>p</i> = 0.020) and higher in the NSAID group than in the non-NSAID groups (47.5 ± 39.5 vs. 15.7 ± 20.0, <i>p</i> = 0.010).</p><p><strong>Conclusion: </strong>This study showed that the clinical characteristics of each causative drug group may be different in drug-induced SJS/TEN. Our findings may help clinicians better understand drug-induced SJS/TEN.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"12 2","pages":"e17"},"PeriodicalIF":1.7,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/6a/apa-12-e17.PMC9066085.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10249438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Asia Pacific Allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1